Genentech, Inc.

Bayer Healthcare LLC

Bayer Pharmaceuticals Corporation

Bayer Intellectual Property Gmbh

University of California

Genetech, Inc.

Bayer Pharma Aktiengesellschaft

Wendy Lee

Jacques P Dumas

Gaetan H Ladouceur

Barton W Phillips

Roger Astbury Smith

Gan Wang

Chengzhi Zhang

William Johnston Scott

Benjamin Jones

James John Crawford

Jianmei Fan

Dhanapalan Nagarathnam

Stephen Colin Price

Stephen J O'Connor

Tatiana Shelekhin

Robert Sibley

Joseph P Lyssikatos

Ann-Marie Campbell

Steven R Magnuson

Robert Andrew Heald

Steven Huy Do

Aleksandr Kolesnikov

Xiaojing Wang

Jacob Bradley Schwarz

Zhonghua Pei

Bernd Riedl

Qian Zhao

Mark Edward Zak

Uday R Khire

Kirk D Robarge

Yuanwei Chen

William H Bullock

Paul Gibbons

Avi J Ashkenazi

John Gary Montana

Fei Wang

Monique Bodil Van Niel

Hazel Joan Dyke

Wendy B Young

Christopher Hurley

Georgette M Castanedo

Vickie Hsiao-Wei Tsui

Kyle E Parcella

Jill E Wood

Andrew Peter Cridland

Xin Ma

Zhi Chen

Stephen Boyer

Ning Miao Su

Joachim Rudolph

Dongping Fan

Qingjie Liu

Michael J Burke

Harold C E Kluender

Cuong Q Ly

Ming Wang

Vickie H Tsui

Mark S Stanley

Nicole Blaquiere

Karen Williams

Kwong Wah Lai

Stuart Ward

Holger Paulsen

Holia Hatoum-Mokdad

Julie A Dixon

Teddy Kite Joe

Derek B Lowe

Simon Mathieu

Quanrong Shen

Robert Dean Dally

Marie-Gabrielle Braun

Ning Qi

Aniko Redman

Sharad Verma

Ramsay Beveridge

Qingming Zhu

Jennifer Burke

Jianqing Chen

Zhaoyang Wen

Scott Wilhelm

Miao Dai

Ignacio Aliagas-Martin

Karl Miranda

Huiyong Hu

Benjamin Fauber

David Gunn

Emanuela Gancia

Mario Lobell

Simon Charles Goodacre

Jason R Zbieg

Alberto Gobbi

Christiana I Iwuagwu

Olivier Rene

Sarah Bronner

Jean-Philippe Leclerc

Jonathan Killen

Du-Shieng Chien

Liang Bao

Paul Winship

Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Phenoxy-pyridyl-pyrimidine compounds and methods of use

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, p, q A, B, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Pyridazine derivatives as RORc modulators

Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I' structure: 

Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazolo[3,4-c]pyridine compounds and methods of use

Heteroaryl pyridone and aza-pyridone amide compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Heteroaryl pyridone and aza-pyridone amide compounds

This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.

Aryl ureas as kinase inhibitors

The present invention relates to compounds of Formula I: wherein R, R, R, A, A, A, A, Yand Yand D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.

N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use

Compounds having the formula I wherein A, R, R, R, R, R, R, R, R, R, R, R, X, X, Xand n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders. 

Serine/threonine kinase inhibitors

Compounds having the formula I wherein A, Z, R, R, R, R, R, R, R, R, R, R, R, Rand n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders. 

Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A=pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g., cytotoxic therapies. 

Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders

This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer. 

Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases

The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity. 

5-anilinoimidazopyridines and methods of use

The present invention relates to compounds of Formula I: wherein R, R, R, A, A, A, Aand D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.

N-9 substituted purine compounds, compositions and methods of use

The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I). 

Substituted pyrazolyl urea derivatives useful in the treatment of cancer

Growing community of inventors

San Ramon, CA, United States of America

Wendy Lee